Professional Documents
Culture Documents
Summary
做為一個典型的 ADC 抗癌藥物,Inotuzumab ozogamicin 有著 antibody 中最長 half life 的
IgG4 antibody 以延長藥物在體內的時間,減少投藥次數,而且藉由此方法提升 specificity。
並結合胞毒性抗生素以彌補 IgG4 antibody 在免疫層面的不足,只利用其作為傳遞胞毒性物
質 NAc ɣ-calicheamicin 的媒介。除了不需經層層活化免疫機制這個過程,不走一般免疫反
應機制也可提高藥物作用的 selectivity,降低對於其他細胞之傷害。雖然仍有些因 NAc ɣ-
calicheamicin 帶來的 side effect,但透過單一 antibody 結合多個胞毒性物質以降低用藥劑量
及前文不斷提及的 specificity、high potency 的藥理性質,其 side effect 已經遠小於非標靶性
的傳統化療抗癌藥物。整體來看,Inotuzumab ozogamicin 可說是汲取了各個結構的長處以
有著比傳統藥物更高的 therapeutic index 與更為顯著的 effect。未來關於 ADC 的相關研究與
發展想必也會越來越多。
References
1
Advani A, Coiffier B, Czuczman MS, et al:Safety, pharmacokinetics, and preliminary clinicalactivity of inotuzumab ozogamicin,
a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: Results of a phase I study. J Clin Oncol 28:2085-
2093, 2010
2
Di Joseph JF, Dougher MM, Kalyandrug LB,et al: Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a
CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin’s B-cell lymphoma.Clin Cancer
Res 12:242-249, 2006
3
BorisShor, Hans-Peter Gerber, PujaSapra, et al:Preclinical and clinical development of inotuzumab-ozogamicin in hematological
malignancies, Molecular Immunology, Volume 67, Issue 2, Part A, October 2015, Pages 107-116
4
O';Reilly MK, Paulson JC. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci 2009;30:240–8
5
Thorson JS, Sievers EL, Ahlert J, et al: Understanding and exploiting nature’s chemical arsenal:The past, present and future of
calicheamicin research.Cur Pharm Des 6:1841-1879, 2000
6
Ricart AD: Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin
Cancer Res 17:6417-6427, 2011
7
P.R. Hamann, L.M. Hinman, I. Hollander, C.F. Beyer, D. Lindh, R. Holcomb, W. Hallett, H.R. Tsou, J. Upeslacis, D. Shochat, et
al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid
leukemia Bioconjug. Chem., 13 (2002), pp. 47-58
8
Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med. 2007;58:221–37.
9
Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective
anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002;13:47–58.
10
Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded
DNA site specifically. Science 1988;240:1198–201.
11
G. Bellomo, M. Vairetti, L. Stivala, F. Mirabelli, P. Richelmi, S. Orrenius, Demonstration of nuclear compartmentalization of
glutathione in hepatocytes, Proc. Natl. Acad. Sci. U.S.A., 89 (1992), pp. 4412-4416
12
J. Drak, N. Iwasawa, S. Danishefsky, D.M. Crothers, The carbohydrate domain of calicheamicin gamma I1 determines its
sequence specificity for DNA cleavage, Proc. Natl. Acad. Sci. U. S. A., 88 (1991), pp. 7464-7468
13
Raponi S, De Propris MS, Intoppa S, et al: Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for
antibody-based immunotherapy in acute lymphoblastic leukemia: Analysis of 52 cases. Leuk Lymphoma 52:1098-1107,2011
14
Wayne AS, Kreitman RJ, Findley HW, et al:Anti-CD22 immunotoxin RFB4 (dsFv)-PE38 (BL22) for CD22-positive
hematologic malignancies of childhood: Preclinical studies and phase I clinical trial. Clin Cancer Res 16:1894-1903, 2010
15
Du X, Beers R, Fitzgerald DJ, et al: Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in
different cytotoxic activity.Cancer Res 68:6300-6305, 2008
16
Xing Du, Richard Beers, David J. FitzGerald and Ira Pastan, Differential Cellular Internalization of Anti-CD19 and -CD22
Immunotoxins Results in Different Cytotoxic Activity, Experimental Therapeutics, Molecular Targets, and Chemical Biology,
(2008), Volume 68, Issue 15
17
J.F. de Vries, C.M. Zwaan, M. De Bie, J.S. Voerman, M.L. den Boer, J.J. van Dongen, V.H. van der Velden, The novel
calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute
lymphoblastic leukemia cells Leukemia, 26 (2012), pp. 255-264
18
Shan D, Constitutive endocytosis and degradation of CD22 by human B cells, Press OW (1995) J Immunol, May 1;
154(9):4466-75.
19
J.F. Di Joseph, M.M. Dougher, D.Y. Evans, B.B. Zhou, N.K. Damle, Preclinical anti-tumor activity of antibody-targeted
chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-
targeted combination chemotherapy with CVP or CHOP, Cancer Chemother. Pharmacol., 67 (2011), pp. 741-749
20
P.R. Hamann, L.M. Hinman, C.F. Beyer, D. Lindh, J. Upeslacis, D.A. Flowers, I. Bernstein, An anti-CD33 antibody-
calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker, Bioconjug. Chem., 13 (2002), pp. 40-46
21
From FDA Professional Drug Information of Inotuzumab ozogamicin
22
John F. Di Joseph, Douglas C. Armellino, Erwin R. Boghaert, Kiran Khandke, et al:Antibody-targeted chemotherapy with
CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies, Blood 2004, pp.
1807-1814
23
Haining WN, Cardoso AA, Keczkemethy HL,et al: Failure to define window of time for autologous tumor vaccination in
patients with newly diagnosedor relapsed acute lymphoblastic leukemia.Exp Hematol 33:286-294, 2005
24
M. Beeram, I.E. Krop, H.A. Burris, S.R. Girish, W. Yu, M.W. Lu, S.N. Holden, S. Modi, A phase 1 study of weekly dosing of
trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer, Cancer, 118
(2012), pp. 5733-5740